News from xencor, inc

May 28, 2014, 08:00 ET

Xencor Initiates Phase 1 Study of XmAb7195 for Asthma

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 22, 2014, 08:00 ET

Xencor to Present at Jefferies 2014 Global Healthcare Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 15, 2014, 08:00 ET

Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 14, 2014, 16:01 ET

Xencor Reports First Quarter 2014 Financial Results

 Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 07, 2014, 08:00 ET

Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Apr 29, 2014, 08:00 ET

Xencor, Inc. to Present at Deutsche Bank 39th Annual Health Care Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Apr 10, 2014, 08:00 ET

Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Mar 28, 2014, 08:00 ET

Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Mar 24, 2014, 08:00 ET

Xencor to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Mar 19, 2014, 16:01 ET

Xencor Reports Fourth Quarter and Full Year 2013 Financial Results

Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Mar 13, 2014, 08:00 ET

Xencor, Inc. to Host Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Feb 06, 2014, 16:01 ET

Xencor to Present at 2014 Leerink Global Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Dec 06, 2013, 12:20 ET

Xencor, Inc. Announces Closing of Initial Public Offering

 Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial...

Dec 03, 2013, 08:00 ET

Xencor Prices Initial Public Offering

 Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of its initial public offering of 12,730,000 shares of its common stock at a public...

Oct 11, 2013, 07:10 ET

Xencor Files Registration Statement for Proposed Initial Public Offering

Xencor, Inc. today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial...

Oct 01, 2013, 16:00 ET

Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease

 Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of...

Jul 02, 2013, 08:00 ET

Xencor Licenses Fc Antibody Engineering IP to Merck

Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the...

Apr 26, 2013, 06:00 ET

Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia

 Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic...

Apr 16, 2013, 08:00 ET

Xencor Licenses Xtend™ Therapeutic Protein Half-life Extension Technology to CSL

Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend...

Feb 13, 2013, 08:00 ET

Xencor Initiates Phase 1b/2a Trial of XmAb®5871 for Autoimmune Disease

 Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer